Day: March 30, 2026

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical development Pro-forma cash and investment balance of $530.2 million as of December 31, 2025 expected to provide runway into early 2029 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. “Over the past six months, Vor Bio repositioned the company around telitacicept and moved quickly to build momentum. We are seeing strong engagement from key opinion leaders and principal investigators,...

Signed First Binding Customer Offtake Agreement with Trafigura Received Indications of Interest for Over $1 Billion in Project Finance Provides an Update on Plans for a Final Investment Decision (“FID”) on the South West Arkansas Project (the “SWA Project”)VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI), a leading near-commercial lithium company, today announced its financial and operating results for the three-month and full year periods ended December 31, 2025. “We had a busy and productive fourth quarter as we advanced and completed multiple important milestones and deliverables for the Company,” said David Park, Chief Executive Officer and Director of Standard Lithium. “We filed a positive Definitive Feasibility Study for...

Reports $46.8M Revenue for 2025 materially ahead of market expectations Exits 2025 at $232M ARR1 with $19.4M December MRR1 Contracted Revenue1 Underpins 2026 Growth Trajectory FY 2026 revenue guidance raised to $360 million; Reiterated 2026 exit ARR1 of $500 million  NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a global leader in Agentic Commerce and AI-powered retail infrastructure, today announced its full-year 2025 results, delivering performance materially ahead of market expectations and moving the business into live, scaled global deployment. Record Revenue: Reported GAAP revenue of $46.8 million for the year. Explosive Exit Velocity: Exited 2025 with a record $19.4M December MRR, representing a $232M+ Annualized Run Rate (ARR), exceeding original guidance of $100 million. Structural Profitability:...

HANGZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) — Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider and crypto treasury company today announced its unaudited financial results as of December 31, 2025 and for the six months ended December 31, 2025. Second Half of 2025 Financial SummaryNet revenue increased by 18.1% to RMB18.7 million (US$2.7 million) for the second half of 2025, from RMB15.9 million in the same period of 2024. Gross loss was RMB29.1 million (US$4.1 million) for the second half of 2025, compared to a gross profit of RMB11.6 million in the same period of 2024. Gain on change in fair value of cryptocurrencies was RMB130.0 million (US$18.5 million) for the second half of 2025, compared to a loss of RMB15.7 million in the same period of 2024. Profit...